Zinzani, P. L. L. Et Al. 2021. Final Analysis of Keynote-170: Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL). BLOOD , vol.138, no.Supplement 1 , 306.

Zinzani, P. L. L., Thieblemont, C., Melnichenko, V., Bouabdallah, K., Waleswski, J., Majlis, A., ... Fogliatto, L.(2021). Final Analysis of Keynote-170: Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL). BLOOD , vol.138, no.Supplement 1, 306.

Zinzani, Pier Et Al. "Final Analysis of Keynote-170: Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL)," BLOOD , vol.138, no.Supplement 1, 306, 2021

Zinzani, Pier L. Et Al. "Final Analysis of Keynote-170: Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL)." BLOOD , vol.138, no.Supplement 1, pp.306, 2021

Zinzani, P. L. L. Et Al. (2021) . "Final Analysis of Keynote-170: Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL)." BLOOD , vol.138, no.Supplement 1, p.306.

@article{article, author={Pier Luigi Luigi Zinzani Et Al. }, title={Final Analysis of Keynote-170: Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL)}, journal={BLOOD}, year=2021, pages={306} }